Challenges in systemic sclerosis trial design.

Area of Science:

• Rheumatology
• Autoimmune Diseases
• Fibrotic Diseases

Background:

• Systemic sclerosis (SSc), or scleroderma, is a severe autoimmune disease characterized by fibrosis and vascular damage.
• SSc has a high mortality rate, with no approved disease-modifying treatments, highlighting a significant unmet medical need.
• Current clinical trial outcome measures, like the modified Rodnan skin score (MRSS), have limitations in reflecting true treatment efficacy.

Purpose of the Study:

• To introduce and discuss the Composite Response Index for Systemic Sclerosis (CRISS) as a novel outcome measure for SSc clinical trials.
• To address the limitations of traditional measures like MRSS in capturing meaningful treatment responses.
• To explore the potential of CRISS in providing a more comprehensive assessment of treatment efficacy for regulatory approval.

Main Methods:

• Development of the CRISS, a composite measure integrating multiple domains: lung function, skin thickness, patient and physician global assessments, and HAQ disability index.
• Provisional acceptance of ACR CRISS by the American College of Rheumatology.
• Evaluation of CRISS's potential to demonstrate clinically meaningful changes beyond traditional metrics.

Main Results:

• The CRISS integrates changes across key domains relevant to SSc patient experience and disease progression.
• While provisionally accepted, CRISS requires demonstration of clinically meaningful changes to persuade health authorities.
• Limitations of MRSS, such as improvement on placebo, necessitate more robust composite measures like CRISS.

Conclusions:

• The CRISS represents a promising advancement in outcome measurement for systemic sclerosis clinical trials.
• Effective evaluation of SSc treatments requires measures that reflect patient-reported outcomes, function, and survival.
• Further validation and demonstration of clinical meaningfulness are crucial for CRISS to impact regulatory approval and patient care.